“Like any new public health intervention, genetically modified mosquitoes raise new questions for researchers, affected communities and other stakeholders,” said Dr Michael Santos, Director of the GeneConvene Global Collaborative.
“The updated guidance framework aims to answer these questions and help ensure that testing of genetically modified mosquitoes is as rigorous as it is for other public health products – and that it generates quality results to guide decisions about if and how these technologies are used.”
“Over the last 2 decades, we have achieved remarkable results with existing malaria control tools, averting more than 7 million deaths and 1.5 billion cases of the disease,” said Dr Pedro Alonso, Director of the WHO Global Malaria Programme.
9114
“然而，我们仍未实现全球防治疟疾战略的关键目标。
“However, progress towards key targets of our global malaria strategy remains off course.
9115
转基因蚊子是一个大有希望的新工具，有助于加快疟疾和其它媒介传播疾病的防治进展。”
Genetically modified mosquitoes are one of a number of promising new tools that could help speed the pace of progress against malaria and other vector-borne diseases.”
“The incidence of dengue continues to increase and affect people in over 129 countries, so we need more sustainable vector control tools to stem the tide of dengue and other arboviral diseases and a few novel tools offer the potential to control these diseases,” said Dr Mwele Malecela, Director of the WHO Department for the Control of Neglected Tropical Diseases.
“We welcome this new guidance from WHO which will help countries suffering from mosquito-borne diseases to evaluate a promising new intervention,” said Professor Aggrey Ambali, Senior Advisor at the African Union Development Agency-New Partnership for Africa’s Development (AUDA-NEPAD), the development agency of the African Union.
9118
新的指南解决了与转基因蚊子的研发工作相关的具体问题和挑战，包括决定如何以及何时进行测试的标准。
The new guidance addresses specific questions and challenges associated with research and development on genetically modified mosquitoes, including standards for decision-making about how and when testing should proceed.
By establishing a common set of expectations that is specific to genetically modified mosquitoes, the new resource will enable more informed and rigorous evaluation by researchers, developers, those responsible for regulatory and policy decisions and the people to whom these stakeholders are accountable.
The guidance builds on an earlier document published by TDR and FNIH in 2014, incorporating the latest scientific advancements related to genetic modification of mosquitoes, as well as other key updates and learnings related to safety and ethics, including: